Back to Market返回行情

PRGO Perrigo Company plc

USHealthcare
$10.22-1.83%ClosedMarket Cap: $1.41B

As of 2026-07-10 16:00

Why PRGO matters now

Perrigo Company plc (PRGO) is a US stock in Healthcare. The latest InvestLog snapshot shows $10.22 with -1.83% on the session and $1.41B in market capitalization; recent performance reads 1-month -3.39% and YTD -26.36%.

The latest financial table shown here is Q1 2026, with revenue of $969.2M, net income of $-398.6M, and EPS of $-2.87. Investors can compare that operating picture with valuation signals such as P/E unavailable and FCF yield 7.6%.

The latest indexable market news headline is "Perrigo Announces Appointment of Two New Independent Directors to Board" from PRNewsWire.

Additional event context on this page matters because analyst consensus is Hold with a median target of $36.00; recent insider activity includes Alford Bradley A filing M-Exempt. These signals are research inputs, not a recommendation.

Valuation

P/E (TTM)

PEG

P/B

0.57

P/S

0.34

EV/EBITDA

-3.93

DCF Value

$364.95

FCF Yield

7.6%

Div Yield

11.3%

Margins & Returns

Gross Margin

34.2%

Operating Margin

5.7%

Net Margin

-43.5%

ROE

-50.7%

ROA

-22.8%

ROIC

3.4%

Financials

PeriodRevenueNet IncomeEPS
Q1 2026$969.2M$-398.6M$-2.87
Q4 2025$1.11B$-1.42B$-10.23
FY 2025$4.25B$-1.43B$-10.29
Q3 2025$1.04B$7.5M$0.05

Analyst Ratings

Consensus

Hold

Target (Consensus)

$36.20

Target (Median)

$36.00

Target Range

$20.00 - $54.00

Strong Buy: 1Buy: 1Hold: 3Sell: 0Strong Sell: 0
Canaccord GenuityBuy
2026-02-27
JP MorganNeutral
2025-12-15
Canaccord GenuityBuy
2025-11-06
JP MorganNeutral
2025-11-06
JefferiesHold
2025-10-27

Trading Activity

Insider Trades

Alford Bradley Adirector
Sell2026-06-16
Alford Bradley Adirector
Sell2026-06-16
Alford Bradley Adirector
Sell2026-06-16
Alford Bradley Adirector
Sell2026-06-16
Manzone Albertdirector, officer: Interim President and CEO
Sell2026-06-16

Company Info

Sector

Healthcare

Industry

Drug Manufacturers - Specialty & Generic

Country

US

Exchange

Beta

0.52

Perrigo Company plc specializes in delivering readily available, non-prescription health and well-being products. Its core mission is to elevate personal health by empowering individuals to proactively manage or address common conditions without professional intervention. The company's operations are strategically divided into two main segments: Consumer Self-Care Americas and Consumer Self-Care International. The Consumer Self-Care Americas division is primarily focused on the creation, production, promotion, and sale of private label self-care products. These offerings span a diverse range of categories, including remedies for upper respiratory issues, pain relief and sleep aids, digestive health, nutritional items (such as vitamins, minerals, and supplements), healthy lifestyle products, skincare, personal hygiene, and oral self-care. This segment serves markets across the United States, Mexico, Canada, and South America. Its product portfolio includes well-known brands like Prevacid 24HR, Good Sense, Zephrex D, ScarAway, Plackers, Rembrandt, Steripod, Firefly, REACH, Dr. Fresh, and Burt's Bees. Conversely, the Consumer Self-Care International segment is dedicated to developing, manufacturing, marketing, and distributing consumer health brands. These products reach consumers through a comprehensive distribution network that includes pharmacies, wholesalers, drugstores, grocery retailers, and para-pharmacies. This segment operates in approximately 23 countries, with a primary focus on the European market. Beyond its own product lines, Perrigo also offers specialized contract manufacturing services. Established in 1887, Perrigo Company plc maintains its corporate headquarters in Dublin, Ireland.